Welcome to NGC. Skip directly to: Search Box, Navigation, Content.

Browse > Guideline Archive > Updated NGC Summaries

Updated NGC Summaries

Use the index below to find guidelines (listed by guideline developer) that have been updated. Select "All" to see a complete list of updated NGC Guideline Summaries (organized alphabetically by guideline developer). In each case the withdrawn guideline has been replaced with a new/revised guideline. For a list of guidelines that have been permanently withdrawn from the site, go to Withdrawn NGC Summaries.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

The National Guideline Clearinghouse™ currently contains 1744 guidelines that have been superceded.

Philippine Academy of Ophthalmology

  1. Clinical practice guideline for the management of cataract among adults. (NGC-2189)
    • Philippine Academy of Ophthalmology. Clinical practice guideline for the management of cataract among adults. Philippines: Philippine Academy of Ophthalmology; 2001. 27 p. [73 references]

    CURRENT NGC SUMMARY: (1) Clinical practice guideline for the management of cataract among adults. (2) Updated recommendation #14. (NGC-4559)

Program in Evidence-based Care

  1. Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma. (NGC-3654)
    • Neuro-Oncology Disease Site Group. Perry J, Zuraw L. Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun [online update]. 14 p. (Practice guideline report; no. 9-2). [32 references]

    CURRENT NGC SUMMARY: Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma: a clinical practice guideline. (NGC-5092)

  2. Adjuvant systemic therapy for node-negative breast cancer. (NGC-2506)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Adjuvant systemic therapy for node-negative breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Feb. Various p. (Practice guideline; no. 1-8). [50 references]

    CURRENT NGC SUMMARY: Adjuvant systemic therapy for node-negative breast cancer. (NGC-3346)

  3. Baseline staging tests in primary breast cancer. (NGC-2441)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Baseline staging tests in primary breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Feb. Various p. (Practice guideline; no. 1-14).


    • Myers RE, Johnston M, Pritchard K, Levine M, Oliver T, Breast Cancer Disease Site Group, Cancer Care Ontario Practice Guidelines Initiative (CCOPGI). Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001 May 15;164(10):1439-44. [34 references] PubMed

    CURRENT NGC SUMMARY: Baseline staging tests in primary breast cancer. (NGC-3345)

  4. Chemotherapy in stage IV (metastatic) non-small cell lung cancer. (NGC-2422)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Chemotherapy in stage IV (metastatic) non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Jan [online update]. Various p. (Practice guideline; no. 7-2). [28 references]

    CURRENT NGC SUMMARY: Chemotherapy in stage IV (metastatic) non-small cell lung cancer. (NGC-5093)

  5. Combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus. (NGC-3264)
    • Gastrointestinal Cancer Disease Site Group. Wong RK, Malthaner RA, Zuraw L, Rumble RB. Combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Aug 18 [online update]. 22 p. (Practice guideline; no. 2-12). [49 references]

    CURRENT NGC SUMMARY: Combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus. (NGC-4572)

  6. Epirubicin, as a single agent or in combination, for metastatic breast cancer. (NGC-2424)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Epirubicin, as a single agent or in combination, for metastatic breast cancer [full report]. Toronto (ON): CCOPGI; 2002 Feb [online update]. Various p. (Practice guideline report; no. 1-6). [14 references]

    CURRENT NGC SUMMARY: Epirubicin, as a single agent or in combination, for metastatic breast cancer. (NGC-3344)

  7. First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (NGC-3458)
    • Gynecology Disease Site Group. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M. First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jan [online update]. 37 p. (Practice guideline report; no. 4-1-2). [64 references]

    CURRENT NGC SUMMARY: First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (NGC-3772)

  8. Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. (NGC-2218)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Nov. Various p. (Practice guideline; no. 5-6b). [19 references]


    • Mackenzie RG, Hodson DI, Browman GP, Zuraw L, Head and Neck Cancer Disease Site Group, Cancer Care Ontario Practice Guidelines Initiative (CCOPGI). Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Curr Oncol 2001;8:6-15. [19 references]

    CURRENT NGC SUMMARY: Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. (NGC-2827)

  9. Management of ductal carcinoma in situ of the breast. (NGC-2927)
    • Breast Cancer Disease Site Group. Management of ductal carcinoma in situ of the breast [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 18 p. (Practice guideline; no. 1-10). [46 references]

    CURRENT NGC SUMMARY: Management of ductal carcinoma in situ of the breast: a clinical practice guideline. (NGC-5344)

  10. Management of single brain metastases. (NGC-3843)
    • Neuro-oncology Disease Site Group. Mintz AP, Perry J, Cairncross G, Chambers A. Management of single brain metastases [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Aug 17. 25 p. (Practice guideline report; no. 9-1). [50 references]

    CURRENT NGC SUMMARY: Management of single brain metastases: a clinical practice guideline. (NGC-5651)

  11. Neoadjuvant chemotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN) (excluding nasopharynx). (NGC-2225)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Neoadjuvant chemotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN) (excluding nasopharynx) [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Jul [online update]. Various p. (Practice guideline; no. 5-1). [36 references]

    CURRENT NGC SUMMARY: The role of neoadjuvant chemotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN) (excluding nasopharynx). (NGC-2925)

  12. Neoadjuvant or adjuvant therapy for resectable esophageal cancer. (NGC-3466)
    • Gastrointestinal Cancer Disease Site Group. Malthaner R, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Apr 16. 28 p. (Practice guideline report; no. 2-11). [51 references]

    CURRENT NGC SUMMARY: Neoadjuvant or adjuvant therapy for resectable esophageal cancer. (NGC-4436)

  13. Optimal therapy for patients diagnosed with multiple myeloma and the role of high-dose chemotherapy and stem cell support. (NGC-2438)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Optimal therapy for patients diagnosed with multiple myeloma and the role of high-dose chemotherapy and stem cell support [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Apr [online update]. Various p. (Practice guideline; no. 6-6). [90 references]


    • Imrie K, Esmail R, Meyer RM. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 2002 Apr 16;136(8):619-29. [44 references] PubMed

    CURRENT NGC SUMMARY: Optimal therapy for patients diagnosed with multiple myeloma and the role of high-dose chemotherapy and stem cell support. (NGC-3539)

  14. Oral capecitabine (Xeloda™) in the first-line treatment of metastatic colorectal cancer. (NGC-3465)
    • Gastrointestinal Cancer Disease Site Group. Kocha W, Maroun J, Jonker D, Rumble RB, Zuraw L. Oral capecitabine (Xeloda) in the first-line treatment of metastatic colorectal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Dec 5. 19 p. (Practice guideline report; no. 2-15). [26 references]

    CURRENT NGC SUMMARY: Oral capecitabine (Xeloda) in the first-line treatment of metastatic colorectal cancer: a clinical practice guideline. (NGC-5094)

  15. Postoperative adjuvant radiation therapy in stage II or IIIA completely resected non-small cell lung cancer. (NGC-3262)
    • Lung Cancer Disease Site Group. Okawara G, Ung YC, Markman BR, Mackay JA, Evans WK. Postoperative adjuvant radiation therapy in stage II or IIIA completely resected non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Aug [online update]. 15 p. (Practice guideline; no. 7-1-1). [14 references]

    CURRENT NGC SUMMARY: Postoperative adjuvant radiation therapy in stage II or IIIA completely resected non-small cell lung cancer. (NGC-4124)

  16. Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation. (NGC-3088)
    • Gynecology Cancer Disease Site Group. Lukka H, Hirte H, Fyles A, Thomas G, Fung Kee Fung M. Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jun [online update]. 25 p. (Practice guideline; no. 4-5). [25 references]

    CURRENT NGC SUMMARY: Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation. (NGC-3773)

  17. Prophylactic cranial irradiation in small cell lung cancer. (NGC-2685)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI), Lung Cancer Disease Site Group. Kotalik J, Yu E, Markman BR, Gagliardi A, Evans WK. Prophylactic cranial irradiation in small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 July [online update]. 14 p. (Practice guideline; no. 7-13-2). [14 references]

    CURRENT NGC SUMMARY: Prophylactic cranial irradiation in small cell lung cancer. (NGC-3347)

  18. Radiotherapy for newly diagnosed malignant glioma in adults. (NGC-3775)
    • Neuro-oncology Disease Site Group. Laperriere N, Perry J, Zuraw L. Radiotherapy for newly diagnosed malignant glioma in adults [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun [online update]. 27 p. (Practice guideline report; no. 9-3). [80 references]

    CURRENT NGC SUMMARY: Radiotherapy for newly diagnosed malignant glioma in adults: a clinical practice guideline. (NGC-4954)

  19. Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical guideline (NGC-4353)
    • Hematology Disease Site Group. Imrie K, Stevens A, Meyer R. Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Feb 17. 43 p. (Evidence-based series; no. 6-8). [51 references]

    CURRENT NGC SUMMARY: Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline. (NGC-5095)

  20. Screening for skin cancer: a clinical practice guideline. (NGC-5025)
    • From L, Marrett L, Johnston M, Mai V, Fong J, Rosen C, Bak K, Sibbald G, Skin Cancer Screening Guideline Panel. Screening for skin cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Mar 15. 32 p. (Evidence-based series; no. 15-1). [70 references]

    CURRENT NGC SUMMARY: Screening for skin cancer: a clinical practice guideline. (NGC-5888)

  21. Surgical management of early stage invasive breast cancer (stage I and II). (NGC-2425)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Surgical management of early stage invasive breast cancer (stage I and II) [full report]. Toronto (ON): CCOPGI; 2002 Jan [online update]. Various p. (Practice guideline report; no. 1-1). [20 references]

    CURRENT NGC SUMMARY: Surgical management of early stage invasive breast cancer. (NGC-2932)

  22. Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients. (NGC-2760)
    • Hodson DI, Haines T, Berry M, Johnston M, Head and Neck Cancer Disease Site Group. Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Oct [online update]. 15 p. (Practice guideline; no. 5-5). [28 references]

    CURRENT NGC SUMMARY: Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients. (NGC-3526)

  23. Systemic adjuvant therapy for patients at high risk for recurrent melanoma. (NGC-3774)
    • Melanoma Disease Site Group. Systemic adjuvant therapy for patients at high risk for recurrent melanoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun 30. 33 p. (Practice guideline report; no. 8-1). [59 references]

    CURRENT NGC SUMMARY: Systemic adjuvant therapy for patients at high risk for recurrent melanoma: a clinical practice guideline. (NGC-5020)

  24. The role of Bevacizumab (Avastin™) combined with chemotherapy in the treatment of patients with advanced colorectal cancer: a clinical practice guideline. (NGC-4866)
    • Welch S, Kocha W, Rumble RB, Spithoff K, Maroun J, Gastrointestinal Cancer Disease Site Group. The role of bevacizumab (Avastin) combined with chemotherapy in the treatment of patients with advanced colorectal cancer. Toronto (ON): Cancer Care Ontario (CCO); 2005 Dec 12. 23 p. (Evidence-based series; no. 2-25). [18 references]

    CURRENT NGC SUMMARY: The role of Bevacizumab (Avastin®) combined with chemotherapy in the treatment of patients with advanced colorectal cancer: a clinical practice guideline. (NGC-6314)

  25. The role of chemotherapy with radiotherapy in the management of patients with newly diagnosed locally advanced squamous cell or undifferentiated nasopharyngeal cancer. (NGC-3527)
    • Head and Neck Cancer Disease Site Group. Thephamongkhol K, Browman G, Hodson I, Oliver T, Zuraw L. The role of chemotherapy with radiotherapy in the management of patients with newly diagnosed locally advanced squamous cell or undifferentiated nasopharyngeal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Mar [online update]. 20 p. (Practice guideline report; no. 5-7). [25 references]

    CURRENT NGC SUMMARY: Chemotherapy with radiotherapy for nasopharyngeal cancer. (NGC-4357)

  26. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. (NGC-2969)
    • Systematic Treatment Disease Site Group. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Mar [online update]. 25 p. (Practice guideline; no. 12-1). [55 references]

    CURRENT NGC SUMMARY: The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. (NGC-4311)

  27. The role of gemcitabine in the management of metastatic breast cancer: a clinical practice guideline. (NGC-5099)
    • Dent S, Messersmith H, Trudeau M, Breast Cancer Disease Site Group. The role of gemcitabine in the management of metastatic breast cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Jun 27. 36 p. (Evidence-based series; no. 1-12). [148 references]

    CURRENT NGC SUMMARY: The role of gemcitabine in the management of metastatic breast cancer: a clinical practice guideline. (NGC-5583)

  28. The role of octreotide in the management of patients with cancer. (NGC-3260)
    • Systemic Treatment Disease Site Group. Major P, Figueredo A, Tandan V, Bramwell V, Charette M, Oliver T. The role of octreotide in the management of patients with cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 May 7. 27 p. (Practice guideline; no. 12-7). [51 references]

    CURRENT NGC SUMMARY: The role of octreotide in the management of patients with cancer. (NGC-4042)

  29. The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first and second-line treatment of advanced colorectal cancer: a clinical practice guideline. (NGC-5345)
    • Jonker D, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first and second-line treatment of advanced colorectal cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Jun 2. 27 p. (Evidence-based series; no. 2-22). [36 references]

    CURRENT NGC SUMMARY: The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first and second-line treatment of advanced colorectal cancer: a clinical practice guideline. (NGC-6242)

  30. The role of single-agent docetaxel (Taxotere®) as a second-line treatment for advanced non-small-cell lung cancer. (NGC-4435)
    • Lung Cancer Disease Site Group. The role of single-agent docetaxel (Taxotere) as a second-line treatment for advanced non-small-cell lung cancer. Toronto (ON): Cancer Care Ontario (CCO); 2005 Jan. 14 p. (Practice guideline report; no. 7-7-2). [16 references]

    CURRENT NGC SUMMARY: Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a clinical practice guideline. (NGC-4953)

  31. The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small cell lung cancer. (NGC-2222)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Oct [online update]. Various p. (Practice guideline; no. 7-13-3). [24 references]


    • Okawara G, Gagliardi A, Evans WK, Lung Cancer Disease Site Group, Cancer Care Ontario Practice Guideline Initiative (CCOPGI). The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer. Curr Oncol 2000;7(3):162-72. [21 references]

    CURRENT NGC SUMMARY: The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small cell lung cancer. (NGC-2991)

  32. The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer. (NGC-2935)
    • Gastrointestinal Cancer Disease Site Group. Figueredo A, Zuraw L, Wong RK, Agboola O, Tandan V. The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Dec [online update]. 23 p. (Practice guideline; no. 2-13). [47 references]

    CURRENT NGC SUMMARY: The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer. (NGC-3461)

  33. Unresected stage III non-small cell lung cancer. (NGC-2928)
    • Lung Cancer Disease Site Group. Unresected stage III non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 22 p. (Practice guideline; no. 7-3). [52 references]

    CURRENT NGC SUMMARY: Management of unresected stage III non-small cell lung cancer: a clinical practice guideline. (NGC-5650)

  34. Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. (NGC-2420)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Jul. Various p. (Practice guideline; no. 12-3). [0 references]


    • Warr D, Bramwell V, Anderson D, Charette M, Systemic Treatment Disease Site Group. Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Curr Oncol 2001;8(2):69-82. [41 references]

    CURRENT NGC SUMMARY: Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. (NGC-2972)

  35. Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder. (NGC-2833)
    • Genitourinary Cancer Disease Site Group. Segal R, Winquist E, Lukka H, Chin L, Brundage M, Markman BR. Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Oct [online update]. 12 p. (Practice guideline report; no. 3-2-1). [19 references]

    CURRENT NGC SUMMARY: Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder. (NGC-3263)

  36. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. (NGC-2226)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Jul [online update]. Various p. (Practice guideline; no. 12-6). [23 references]


    • Cancer Care Ontario Practice Guideline Initiative. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Curr Oncol 2000;7(3):149-61. [23 references]

    CURRENT NGC SUMMARY: Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. (NGC-2929)

  37. Use of bisphosphonates in women with breast cancer. (NGC-2931)
    • Breast Cancer Disease Site Group. Use of bisphosphonates in patients with breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Dec [online update]. 23 p. (Practice guideline; no. 1-11). [59 references]

    CURRENT NGC SUMMARY: Use of bisphosphonates in women with breast cancer. (NGC-3770)

  38. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. (NGC-2584)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Jun [online update]. Various p. (Practice guideline; no. 12-5). [23 references]

    CURRENT NGC SUMMARY: Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. (NGC-3488)

  39. Use of gemcitabine in the treatment of advanced pancreatic adenocarcinoma. (NGC-3348)
    • Gastrointestinal Cancer Disease Site Group. Germond C, Maroun J, Moore M, Zwaal C, Wong S. Use of gemcitabine in the treatment of advanced pancreatic adenocarcinoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jun 24 [online update]. 15 p. (Practice guideline report; no. 2-10). [19 references]

    CURRENT NGC SUMMARY: Use of gemcitabine in the treatment of advanced pancreatic adenocarcinoma. (NGC-5096)

  40. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. (NGC-2763)
    • Rusthoven J, Bramwell V, Stephenson B, Provincial Systemic Treatment Disease Site Group. Use of granulocyte colony stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Nov [online update]. 16 p. (Practice guideline; no. 12-2). [76 references]

    CURRENT NGC SUMMARY: The role of colony-stimulating factor (CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. (NGC-3460)

  41. Use of irinotecan (Camptosar®, CPT-11) combined with 5-fluorouracil and leucovorin (5FU/LV) as first line therapy for metastatic colorectal cancer. (NGC-2419)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of irinotecan (Camptosar, CPT-11) combined with 5-fluorouracil and leucovorin (5FU/LV) as first line therapy for metastatic colorectal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2001 Oct. Various p. (Practice guideline; no. 2-16b). [13 references]


    • Jonker D, Earle C, Kocha W, Moore M, Maroun J, Zuraw L, Gastrointestinal Cancer Disease Site Group. Use of irinotecan combined with 5-fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. Curr Oncol 2001;8(2):60-8. [13 references]

    CURRENT NGC SUMMARY: Use of irinotecan (Camptosar®, CPT-11) combined with 5-fluorouracil and leucovorin (5FU/LV) as first-line therapy for metastatic colorectal cancer. (NGC-2989)

  42. Use of irinotecan in the treatment of metastatic colorectal carcinoma. (NGC-3464)
    • Gastrointestinal Cancer Disease Site Group. Figueredo A, Moore M, Germond C, Kocha W, Maroun J, Zwaal C. Use of irinotecan in the treatment of metastatic colorectal carcinoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Dec [online update]. 15 p. (Practice guideline report; no. 2-16). [20 references]

    CURRENT NGC SUMMARY: Use of irinotecan in the second-line treatment of metastatic colorectal carcinoma. (NGC-4358)

  43. Use of raltitrexed (Tomudex) in the management of metastatic colorectal carcinoma. (NGC-2926)
    • Gastrointestinal Cancer Disease Site Group. Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer. Toronto (ON): Cancer Care Ontario (CCO); 2003 Feb [online update]. 16 p. (Practice guideline; no. 2-17). [22 references]

    CURRENT NGC SUMMARY: Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer. (NGC-4434)

Public Health Service (U.S.)

  1. Treating tobacco use and dependence. A clinical practice guideline. (NGC-1586)
    • U.S. Department of Health and Human Services, Public Health Service. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service; 2000 Jun. 197 p. [311 references]

    CURRENT NGC SUMMARY: Treating tobacco use and dependence: 2008 update. (NGC-6444)


Search Help
Detailed Search
Frequent Searches